Search results for: Multi-Indication Medicines
Filter search results
Differential Pricing – A Win-Win Solution?
2 March 2011
…higher prices have been established elsewhere’ thus delaying access by patients to new medicines. In extreme cases, companies may decide to not market a medicine at all in a particular…
Does Relative Effectiveness Vary Across Europe?
9 August 2011
At the Spanish Health Economics Association (AES) conference in May 2011, OHE’s Ruth Puig Peiró discussed a recent OHE study that reviewed the available literature on variations in medicines’ efficacy…
Previews of Forthcoming Publications
27 July 2011
…of the problem of insufficient affordable medicines in developing countries and detail policies and proposals intended to increase access to global medicines. With respect to neglected diseases, the paper examines policies…
New: Operationalising Value Based Pricing
11 August 2011
…by NICE. The Department of Health has stated that it will include “the range of factors through which medicines deliver benefits for patients and society”. To date, the UK Government…
Spotlight on OHE: Measuring Preferences, HTA Benchmarking, Value-Based Pricing, and Rationing
13 October 2011
…R&D in global health. Value-based pricing (VBP), due to be implemented in the UK for newly marketed medicines as from 2014, remains a key focus of OHE activities. At a…
Is It Time to Reconsider the Role of Co-Payments in Europe?
11 January 2012
…many countries, primarily for medicines, and designed to achieve one of two objectives. The first has been to reduce moral hazard by requiring patients to pay an ‘entry fee’ to…
New: 50 Years of OHE Publications Are Available Online
2 April 2012
…1968 Medicines Act made prior approval mandatory and created the Committee on the Safety of Medicines. 1962 also was the year that Sir James Black discovered the first clinically significant…
OHE Conference on Drug Development in 2022: Update
18 July 2012
…Robin Evers, Vice President, Worldwide Regulatory Strategy, Pfizer Ltd. Dr Menelas Pangalos, Executive VP of Innovative Medicines, AstraZeneca They join: Dr Richard Barker, Director of the Centre for Accelerating Medical…
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
31 January 2013
Just out in the International Journal of Technology Assessment in Health Care is an important new study that reviews appraisals of breast cancer and colorectal cancer medicines by HTA agencies…